CorMedix Inc. Bolsters Growth with $300M Acquisition of Melinta Therapeutics Amid Strong Financial Performance
CorMedix Inc. has made a strategic acquisition of Melinta Therapeutics, valued at $300 million, to create a diversified specialty company with a strong presence in acute care settings.
2 minutes to read